NSG 554 FNP Exam 1 Prep Document | 2026/2027 Edition |
250 Verified Questions
NSG 554 FNP Exam 1 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive test bank for NSG 554 Exam 1 (Wilkes University) contains 250 verified
questions covering essential content for the Family Nurse Practitioner (FNP) program. Designed to
reflect the latest 2026/2027 curriculum and clinical guidelines, this resource provides thorough
preparation for the exam. Each question includes detailed rationales and evidence-based explanations
to reinforce learning and ensure mastery of advanced practice nursing concepts.
Key Features:
Health Assessment and Differential Diagnosis
Pharmacology for Advanced Practice
Management of Common Acute and Chronic Conditions
Evidence-Based Practice and Clinical Guidelines
Patient Education and Health Promotion
Legal and Ethical Issues in Advanced Practice Nursing
Updates for 2026:
- Updated to reflect 2026/2027 AACN and AANP guidelines
- Incorporates latest evidence-based practice recommendations
- Revised pharmacology content with new drug classifications
- Enhanced rationales with current clinical references
- Added questions on telehealth and remote patient management
Abstract:
The NSG 554 Exam 1 Test Bank for the 2026/2027 academic year is a meticulously curated collection of 250
questions designed to assess and reinforce the knowledge required for the Family Nurse Practitioner (FNP)
certification. This resource aligns with the Wilkes University curriculum and national competencies, covering
health assessment, pharmacology, and management of common conditions across the lifespan. Each question is
accompanied by a detailed rationale that explains the correct answer and distractor analysis, promoting critical
thinking and clinical reasoning. The test bank incorporates the latest updates from the American Association of
Nurse Practitioners (AANP) and the American Nurses Credentialing Center (ANCC), ensuring relevance to current
practice. By utilizing this resource, students can identify knowledge gaps, build confidence, and achieve a high
level of preparedness for the exam. The structured format, with questions organized by content area and difficulty,
facilitates targeted study and efficient review. This test bank is an essential tool for FNP students aiming to excel in
their advanced practice education and future clinical roles.
Keywords:
NSG 554 Exam 1, FNP test bank, Wilkes University, advanced practice nursing, health assessment, pharmacology,
differential diagnosis, clinical guidelines
Answer Format:
Each question is followed by the correct answer and a comprehensive rationale explaining why it is correct, along
with analysis of incorrect options. Distractors are addressed to clarify common misconceptions. Rationales are
evidence-based and reference current clinical guidelines.
Compliance Checklist:
Aligned with 2026/2027 AANP and ANCC competencies
Page 1
, Updated per latest evidence-based practice guidelines
Covers all major content areas for NSG 554 Exam 1
Includes rationales for correct and incorrect answers
Questions reviewed by subject matter experts
Suitable for self-assessment and exam preparation
Content Area Overview:
Content Area Questions Key Topics Weight
Health Assessment and 1-60 Comprehensive history taking, physical 24%
Differential Diagnosis examination techniques, diagnostic
reasoning, common differential diagnoses
Pharmacology for Advanced 61-110 Pharmacokinetics, pharmacodynamics, drug 20%
Practice interactions, prescribing for common
conditions, controlled substances
Management of Acute 111-160 Respiratory infections, urinary tract 20%
Conditions infections, skin infections, minor injuries,
acute pain management
Management of Chronic 161-210 Hypertension, diabetes, asthma, COPD, 20%
Conditions hyperlipidemia, heart failure
Evidence-Based Practice and 211-235 Critical appraisal of literature, applying 10%
Clinical Guidelines guidelines to practice, quality improvement,
patient safety
Legal, Ethical, and Professional 236-250 Scope of practice, informed consent, 6%
Issues confidentiality, ethical dilemmas,
reimbursement
Page 2
,Q1. A patient with type 2 diabetes and chronic kidney disease (GFR 35 mL/min) has been on
metformin 1000 mg twice daily. Recent lab results show worsening renal function (GFR 28
mL/min). According to current FDA guidelines, which of the following actions is most appropriate
regarding metformin therapy?
A. Continue metformin at the same dose but monitor GFR monthly.
B. Reduce metformin dose to 500 mg twice daily.
C. Discontinue metformin and initiate an alternative agent.
D. Switch to metformin extended-release formulation.
Correct Answer: C. Discontinue metformin and initiate an alternative agent.
Rationale: Metformin is contraindicated when GFR falls below 30 mL/min due to increased risk of lactic
acidosis. Current FDA guidelines recommend discontinuing metformin when GFR <30 mL/min. Reducing
the dose or switching to extended-release does not mitigate the risk, as the drug accumulation remains a
concern. Alternative agents such as SGLT2 inhibitors or GLP-1 receptor agonists are preferred in this
setting.
Why Wrong:
A - Continuing metformin at GFR <30 mL/min increases the risk of lactic acidosis, which is
potentially fatal.
B - Even a reduced dose at GFR <30 mL/min carries significant risk; guidelines recommend
discontinuation.
D - Extended-release metformin has the same renal clearance and contraindication as
immediate-release.
Reference: FDA Drug Safety Communication (2024) on metformin contraindications in renal
impairment; ADA Standards of Medical Care in Diabetes, 2026.
Q2. A patient with hypertension and moderate hepatic impairment (Child-Pugh Class B) requires
antihypertensive therapy. Which of the following beta-blockers is safest to use in this patient?
A. Propranolol
B. Labetalol
C. Atenolol
D. Metoprolol
Correct Answer: C. Atenolol
Rationale: Atenolol is predominantly renally excreted (85-90% unchanged), minimizing hepatic
metabolism and making it safer in hepatic impairment. Propranolol, labetalol, and metoprolol undergo
extensive first-pass hepatic metabolism, leading to unpredictable bioavailability and potential
accumulation in liver disease.
Why Wrong:
A - Propranolol undergoes extensive hepatic metabolism; its bioavailability increases unpredictably
in liver disease.
B - Labetalol has significant hepatic metabolism and is not preferred in hepatic impairment.
D - Metoprolol is metabolized by CYP2D6 in the liver; hepatic impairment can lead to increased
levels and bradycardia.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 19; FDA labeling for
atenolol.
Page 3
, Q3. A patient with a history of atrial fibrillation is started on warfarin for stroke prophylaxis. Three
days into therapy, the INR is 1.2. The patient is also taking amiodarone for rhythm control. What is
the most likely effect of amiodarone on warfarin metabolism, and how should the warfarin dose be
adjusted?
A. Amiodarone inhibits warfarin metabolism; decrease warfarin dose.
B. Amiodarone induces warfarin metabolism; increase warfarin dose.
C. Amiodarone has no significant interaction; no dose adjustment needed.
D. Amiodarone potentiates warfarin via protein binding displacement; maintain current dose.
Correct Answer: A. Amiodarone inhibits warfarin metabolism; decrease warfarin dose.
Rationale: Amiodarone is a potent inhibitor of CYP2C9, the primary enzyme responsible for metabolizing
S-warfarin, leading to increased warfarin effect and INR. Even at subtherapeutic INR early in therapy,
the interaction requires a dose reduction to prevent supratherapeutic INR later. Induction (option B) is
incorrect; amiodarone inhibits, not induces. The interaction is metabolic, not protein-binding
displacement (option D).
Why Wrong:
B - Amiodarone is an inhibitor, not an inducer, of CYP2C9.
C - A significant interaction exists; amiodarone increases warfarin levels and bleeding risk.
D - The interaction is primarily metabolic inhibition, not protein binding displacement.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34; Micromedex Drug
Interactions Database.
Q4. A patient with major depressive disorder has been on fluoxetine 40 mg daily for 6 weeks with
minimal improvement. The clinician considers adding a second agent. Which of the following
augmentation strategies is most supported by current evidence for treatment-resistant depression?
A. Add aripiprazole 2 mg daily
B. Add bupropion 150 mg twice daily
C. Switch to venlafaxine 150 mg daily
D. Add lithium 300 mg twice daily
Correct Answer: A. Add aripiprazole 2 mg daily
Rationale: Aripiprazole is an FDA-approved augmentation agent for major depressive disorder (MDD)
when response to SSRI monotherapy is inadequate. Bupropion augmentation is also used but has less
robust evidence for treatment-resistant depression compared to atypical antipsychotics. Venlafaxine is a
switch strategy, not augmentation. Lithium augmentation is effective but is second-line due to monitoring
requirements and tolerability.
Why Wrong:
B - Bupropion is used as augmentation but is not FDA-approved for this indication; evidence is
weaker than for aripiprazole.
C - Switching to venlafaxine is a different strategy (not augmentation) and may be considered but is
not the best-supported augmentation option.
D - Lithium augmentation is effective but is considered second-line due to need for serum
monitoring and side effects.
Reference: American Psychiatric Association (2024). Practice Guideline for the Treatment of Patients
with Major Depressive Disorder, 4th Ed.; STAR*D trial.
Page 4
250 Verified Questions
NSG 554 FNP Exam 1 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive test bank for NSG 554 Exam 1 (Wilkes University) contains 250 verified
questions covering essential content for the Family Nurse Practitioner (FNP) program. Designed to
reflect the latest 2026/2027 curriculum and clinical guidelines, this resource provides thorough
preparation for the exam. Each question includes detailed rationales and evidence-based explanations
to reinforce learning and ensure mastery of advanced practice nursing concepts.
Key Features:
Health Assessment and Differential Diagnosis
Pharmacology for Advanced Practice
Management of Common Acute and Chronic Conditions
Evidence-Based Practice and Clinical Guidelines
Patient Education and Health Promotion
Legal and Ethical Issues in Advanced Practice Nursing
Updates for 2026:
- Updated to reflect 2026/2027 AACN and AANP guidelines
- Incorporates latest evidence-based practice recommendations
- Revised pharmacology content with new drug classifications
- Enhanced rationales with current clinical references
- Added questions on telehealth and remote patient management
Abstract:
The NSG 554 Exam 1 Test Bank for the 2026/2027 academic year is a meticulously curated collection of 250
questions designed to assess and reinforce the knowledge required for the Family Nurse Practitioner (FNP)
certification. This resource aligns with the Wilkes University curriculum and national competencies, covering
health assessment, pharmacology, and management of common conditions across the lifespan. Each question is
accompanied by a detailed rationale that explains the correct answer and distractor analysis, promoting critical
thinking and clinical reasoning. The test bank incorporates the latest updates from the American Association of
Nurse Practitioners (AANP) and the American Nurses Credentialing Center (ANCC), ensuring relevance to current
practice. By utilizing this resource, students can identify knowledge gaps, build confidence, and achieve a high
level of preparedness for the exam. The structured format, with questions organized by content area and difficulty,
facilitates targeted study and efficient review. This test bank is an essential tool for FNP students aiming to excel in
their advanced practice education and future clinical roles.
Keywords:
NSG 554 Exam 1, FNP test bank, Wilkes University, advanced practice nursing, health assessment, pharmacology,
differential diagnosis, clinical guidelines
Answer Format:
Each question is followed by the correct answer and a comprehensive rationale explaining why it is correct, along
with analysis of incorrect options. Distractors are addressed to clarify common misconceptions. Rationales are
evidence-based and reference current clinical guidelines.
Compliance Checklist:
Aligned with 2026/2027 AANP and ANCC competencies
Page 1
, Updated per latest evidence-based practice guidelines
Covers all major content areas for NSG 554 Exam 1
Includes rationales for correct and incorrect answers
Questions reviewed by subject matter experts
Suitable for self-assessment and exam preparation
Content Area Overview:
Content Area Questions Key Topics Weight
Health Assessment and 1-60 Comprehensive history taking, physical 24%
Differential Diagnosis examination techniques, diagnostic
reasoning, common differential diagnoses
Pharmacology for Advanced 61-110 Pharmacokinetics, pharmacodynamics, drug 20%
Practice interactions, prescribing for common
conditions, controlled substances
Management of Acute 111-160 Respiratory infections, urinary tract 20%
Conditions infections, skin infections, minor injuries,
acute pain management
Management of Chronic 161-210 Hypertension, diabetes, asthma, COPD, 20%
Conditions hyperlipidemia, heart failure
Evidence-Based Practice and 211-235 Critical appraisal of literature, applying 10%
Clinical Guidelines guidelines to practice, quality improvement,
patient safety
Legal, Ethical, and Professional 236-250 Scope of practice, informed consent, 6%
Issues confidentiality, ethical dilemmas,
reimbursement
Page 2
,Q1. A patient with type 2 diabetes and chronic kidney disease (GFR 35 mL/min) has been on
metformin 1000 mg twice daily. Recent lab results show worsening renal function (GFR 28
mL/min). According to current FDA guidelines, which of the following actions is most appropriate
regarding metformin therapy?
A. Continue metformin at the same dose but monitor GFR monthly.
B. Reduce metformin dose to 500 mg twice daily.
C. Discontinue metformin and initiate an alternative agent.
D. Switch to metformin extended-release formulation.
Correct Answer: C. Discontinue metformin and initiate an alternative agent.
Rationale: Metformin is contraindicated when GFR falls below 30 mL/min due to increased risk of lactic
acidosis. Current FDA guidelines recommend discontinuing metformin when GFR <30 mL/min. Reducing
the dose or switching to extended-release does not mitigate the risk, as the drug accumulation remains a
concern. Alternative agents such as SGLT2 inhibitors or GLP-1 receptor agonists are preferred in this
setting.
Why Wrong:
A - Continuing metformin at GFR <30 mL/min increases the risk of lactic acidosis, which is
potentially fatal.
B - Even a reduced dose at GFR <30 mL/min carries significant risk; guidelines recommend
discontinuation.
D - Extended-release metformin has the same renal clearance and contraindication as
immediate-release.
Reference: FDA Drug Safety Communication (2024) on metformin contraindications in renal
impairment; ADA Standards of Medical Care in Diabetes, 2026.
Q2. A patient with hypertension and moderate hepatic impairment (Child-Pugh Class B) requires
antihypertensive therapy. Which of the following beta-blockers is safest to use in this patient?
A. Propranolol
B. Labetalol
C. Atenolol
D. Metoprolol
Correct Answer: C. Atenolol
Rationale: Atenolol is predominantly renally excreted (85-90% unchanged), minimizing hepatic
metabolism and making it safer in hepatic impairment. Propranolol, labetalol, and metoprolol undergo
extensive first-pass hepatic metabolism, leading to unpredictable bioavailability and potential
accumulation in liver disease.
Why Wrong:
A - Propranolol undergoes extensive hepatic metabolism; its bioavailability increases unpredictably
in liver disease.
B - Labetalol has significant hepatic metabolism and is not preferred in hepatic impairment.
D - Metoprolol is metabolized by CYP2D6 in the liver; hepatic impairment can lead to increased
levels and bradycardia.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 19; FDA labeling for
atenolol.
Page 3
, Q3. A patient with a history of atrial fibrillation is started on warfarin for stroke prophylaxis. Three
days into therapy, the INR is 1.2. The patient is also taking amiodarone for rhythm control. What is
the most likely effect of amiodarone on warfarin metabolism, and how should the warfarin dose be
adjusted?
A. Amiodarone inhibits warfarin metabolism; decrease warfarin dose.
B. Amiodarone induces warfarin metabolism; increase warfarin dose.
C. Amiodarone has no significant interaction; no dose adjustment needed.
D. Amiodarone potentiates warfarin via protein binding displacement; maintain current dose.
Correct Answer: A. Amiodarone inhibits warfarin metabolism; decrease warfarin dose.
Rationale: Amiodarone is a potent inhibitor of CYP2C9, the primary enzyme responsible for metabolizing
S-warfarin, leading to increased warfarin effect and INR. Even at subtherapeutic INR early in therapy,
the interaction requires a dose reduction to prevent supratherapeutic INR later. Induction (option B) is
incorrect; amiodarone inhibits, not induces. The interaction is metabolic, not protein-binding
displacement (option D).
Why Wrong:
B - Amiodarone is an inhibitor, not an inducer, of CYP2C9.
C - A significant interaction exists; amiodarone increases warfarin levels and bleeding risk.
D - The interaction is primarily metabolic inhibition, not protein binding displacement.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34; Micromedex Drug
Interactions Database.
Q4. A patient with major depressive disorder has been on fluoxetine 40 mg daily for 6 weeks with
minimal improvement. The clinician considers adding a second agent. Which of the following
augmentation strategies is most supported by current evidence for treatment-resistant depression?
A. Add aripiprazole 2 mg daily
B. Add bupropion 150 mg twice daily
C. Switch to venlafaxine 150 mg daily
D. Add lithium 300 mg twice daily
Correct Answer: A. Add aripiprazole 2 mg daily
Rationale: Aripiprazole is an FDA-approved augmentation agent for major depressive disorder (MDD)
when response to SSRI monotherapy is inadequate. Bupropion augmentation is also used but has less
robust evidence for treatment-resistant depression compared to atypical antipsychotics. Venlafaxine is a
switch strategy, not augmentation. Lithium augmentation is effective but is second-line due to monitoring
requirements and tolerability.
Why Wrong:
B - Bupropion is used as augmentation but is not FDA-approved for this indication; evidence is
weaker than for aripiprazole.
C - Switching to venlafaxine is a different strategy (not augmentation) and may be considered but is
not the best-supported augmentation option.
D - Lithium augmentation is effective but is considered second-line due to need for serum
monitoring and side effects.
Reference: American Psychiatric Association (2024). Practice Guideline for the Treatment of Patients
with Major Depressive Disorder, 4th Ed.; STAR*D trial.
Page 4
